Efficacy of Anrikefon-based Patient-controlled Intravenous Analgesia for Pain Management After Laparoscopic Surgery: a Randomized, Double-blind, Active-controlled Pilot Trial

What this Trial Is About

Researchers are evaluating the use of anrikefon, a new type of pain medicine that targets specific receptors related to visceral pain, for managing pain after laparoscopic surgery. This study focuses on patients undergoing laparoscopic colorectal surgery, aiming to find the best dose of anrikefon given through a patient-controlled intravenous analgesia (PCIA) pump. The goal is to specifically reduce visceral pain, which is often underestimated and not well controlled by usual pain medicines like morphine. Participants will receive postoperative pain management with one of four treatments: high-dose anrikefon, medium-dose anrikefon, low-dose anrikefon, or morphine. Each treatment is delivered via a PCIA pump programmed to give an initial dose followed by patient-controlled bolus doses with a lockout period, over 48 hours. The treatments are combined with other pain control methods like nerve blocks for somatic pain and nonsteroidal anti-inflammatory drugs (NSAIDs) for inflammatory pain as part of a multimodal approach. During the study, participants will be monitored closely for pain levels at rest and with movement over 48 hours after surgery using pain intensity measures. Researchers will assess the area under the curve (AUC) of visceral and overall pain to evaluate effectiveness. Safety and side effects will also be observed. The study is designed as a randomized, double-blind, active-controlled trial, helping determine the feasibility of a larger future study and optimal dosing for anrikefon in this setting.

Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery